Santen Pharmaceutical Co., Ltd.
Other OTCTotal Valuation
Santen Pharmaceutical Co., Ltd. carries a market capitalization of 3.54B, placing it among publicly traded companies globally. Its enterprise value stands at 519.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.54B |
| Enterprise Value | 519.54B |
Share Statistics
Santen Pharmaceutical Co., Ltd. currently has 349.15M shares outstanding.
| Shares Outstanding | 349.15M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Santen Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 82.35. The price-to-sales ratio is 3.88, and the price-to-book ratio stands at 2.32.
| PE Ratio | 82.35 |
| PS Ratio | 3.88 |
| PB Ratio | 2.32 |
| P/TBV Ratio | 2.90 |
| P/FCF Ratio | 12.07 |
| P/OCF Ratio | 13.50 |
Enterprise Valuation
On an enterprise value basis, Santen Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 38.66 and an EV/FCF ratio of 9.72. The EV/Sales ratio of 3.33 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 38.66 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.33 |
| EV / EBITDA | 38.66 |
| EV / EBIT | 38.66 |
| EV / FCF | 9.72 |
Financial Position
Santen Pharmaceutical Co., Ltd. maintains a current ratio of 2.61, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.61 |
| Quick Ratio | 1.02 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 5.63 |
Financial Efficiency
Santen Pharmaceutical Co., Ltd. posts a return on equity of 2.82 and a return on invested capital of 9.95.
| Return on Equity (ROE) | 2.82 |
| Return on Assets (ROA) | 1.76 |
| Return on Invested Capital (ROIC) | 9.95 |
| Return on Capital Employed (ROCE) | 10.83 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.29 |
Taxes
Over the trailing twelve months, Santen Pharmaceutical Co., Ltd. has paid -1.63B in income taxes, reflecting an effective tax rate of 22.98.
| Income Tax | -1.63B |
| Effective Tax Rate | 22.98 |
Stock Price Statistics
Santen Pharmaceutical Co., Ltd.'s stock has declined approximately -0.09090909% over the past 52 weeks. The 50-day moving average sits at 10.99, while the 200-day moving average is 10.44.
| Beta (5Y) | N/A |
| 52-Week Price Change | -0.09090909% |
| 50-Day Moving Average | 10.99 |
| 200-Day Moving Average | 10.44 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Santen Pharmaceutical Co., Ltd. generated 156.16B in revenue and converted that into 7.36B in net income, yielding earnings per share of 20.77. EBITDA reached 13.44B, while operating income came in at 13.44B.
| Revenue | 156.16B |
| Gross Profit | 92.36B |
| Operating Income | 13.44B |
| Pretax Income | 5.80B |
| Net Income | 7.36B |
| EBITDA | 13.44B |
| EBIT | 13.44B |
| Earnings Per Share (EPS) | 20.77 |
Balance Sheet
Total book value stands at 261.73B, with working capital of 134.61B providing operational flexibility.
| Cash & Cash Equivalents | 85.92B |
| Total Debt | N/A |
| Net Debt | -84.44B |
| Equity (Book Value) | 261.73B |
| Book Value Per Share | 734.19 |
| Working Capital | 134.61B |
Cash Flow
Santen Pharmaceutical Co., Ltd. produced 44.92B in operating cash flow over the past twelve months. After subtracting -5.49B in capital expenditures, free cash flow totaled 39.43B - equivalent to 110.59 per share.
| Operating Cash Flow | 44.92B |
| Capital Expenditures | -5.49B |
| Free Cash Flow | 39.43B |
| FCF Per Share | 110.59 |
Margins
Santen Pharmaceutical Co., Ltd. operates with a gross margin of 59.14, reflecting its pricing power and cost economics. The operating margin of 8.61 and net profit margin of 4.71 provide insight into operational efficiency.
| Gross Margin | 59.14 |
| Operating Margin | 8.61 |
| Pretax Margin | 3.71 |
| Profit Margin | 4.71 |
| EBITDA Margin | 8.61 |
Dividends & Yields
The company's payout ratio of 78.37 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 16.47 |
| Dividend Yield | N/A |
| Payout Ratio | 78.37 |
| Shareholder Yield | 2.37 |
| FCF Yield | 8.29 |
Stock Splits
Santen Pharmaceutical Co., Ltd.'s most recent stock split took place on March 27, 2015 with a 1:5 split ratio.
| Last Split Date | 3/27/2015 |
| Split Ratio | 1:5 |
Scores
Santen Pharmaceutical Co., Ltd. posts an Altman Z-Score of 5.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.18 |